Johnson & Johnson (JNJ) EBT (2009 - 2026)
Johnson & Johnson recorded quarterly EBT of $6.0 billion in Q1 2026, up 20.62% quarter-over-quarter from $5.0 billion in Q4 2025, and down 56.06% year-over-year from $13.6 billion in Q1 2025.
Johnson & Johnson's EBT history runs 18 years deep, the most recent figure standing at $6.0 billion for Q1 2026.
- In Q1 2026, EBT fell 56.06% year-over-year to $6.0 billion; the TTM figure through Mar 2026 stood at $24.9 billion (down 6.25% YoY), while the FY2025 annual figure was $32.6 billion, up 95.25% from the prior year.
- EBT came in at $6.0 billion for Q1 2026 at Johnson & Johnson, up from $5.0 billion in the prior quarter.
- In the past five years, EBT ranged from a high of $13.6 billion in Q1 2025 to a low of -$1.3 billion in Q2 2023.
- A 5-year average of $5.3 billion and a median of $5.2 billion in 2022 frame the typical range for EBT.
- Across the five-year window, EBT tumbled 124.74% in 2023 and surged 388.58% in 2024, its largest moves.
- Johnson & Johnson's EBT stood at $5.2 billion in 2022, then decreased by 6.69% to $4.8 billion in 2023, then declined by 19.46% to $3.9 billion in 2024, then increased by 27.76% to $5.0 billion in 2025, then rose by 20.62% to $6.0 billion in 2026.
- According to Business Quant data, EBT over the past three periods registered $6.0 billion, $5.0 billion, and $7.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 8.85 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 5.99 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 1.04 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -3.50 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 2.08 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 2.58 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 3.17 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 3.24 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 5.99 Bn |
| Dec 28, 2025 | 4.97 Bn |
| Sep 28, 2025 | 7.49 Bn |
| Jun 29, 2025 | 6.49 Bn |
| Mar 30, 2025 | 13.63 Bn |
| Dec 29, 2024 | 3.89 Bn |
| Sep 29, 2024 | 3.34 Bn |
| Jun 30, 2024 | 5.75 Bn |
| Mar 31, 2024 | 3.71 Bn |
| Dec 31, 2023 | 4.83 Bn |
| Oct 1, 2023 | 5.22 Bn |
| Jul 2, 2023 | 6.31 Bn |
| Apr 2, 2023 | -1.29 Bn |
| Jan 1, 2023 | 3.84 Bn |
| Oct 2, 2022 | 5.17 Bn |
| Jul 3, 2022 | 5.14 Bn |
| Apr 3, 2022 | 5.20 Bn |
| Oct 3, 2021 | 3.85 Bn |
| Jul 4, 2021 | 6.66 Bn |
| Apr 4, 2021 | 7.43 Bn |
| Jan 3, 2021 | 1.65 Bn |
| Sep 27, 2020 | 4.40 Bn |
| Jun 28, 2020 | 3.94 Bn |
| Mar 29, 2020 | 6.51 Bn |
| Dec 29, 2019 | 4.22 Bn |
| Sep 29, 2019 | 1.65 Bn |
| Jun 30, 2019 | 7.04 Bn |
| Mar 31, 2019 | 4.42 Bn |
| Dec 30, 2018 | 3.12 Bn |
| Sep 30, 2018 | 4.42 Bn |
| Jul 1, 2018 | 4.97 Bn |
| Apr 1, 2018 | 5.48 Bn |
| Dec 31, 2017 | 2.56 Bn |
| Oct 1, 2017 | 4.79 Bn |
| Jul 2, 2017 | 4.75 Bn |
| Apr 2, 2017 | 5.58 Bn |
| Jan 1, 2017 | 4.32 Bn |
| Oct 2, 2016 | 5.28 Bn |
| Jul 3, 2016 | 4.90 Bn |
| Apr 3, 2016 | 5.29 Bn |
| Jan 3, 2016 | 3.76 Bn |
| Sep 27, 2015 | 4.12 Bn |
| Jun 28, 2015 | 5.74 Bn |
| Mar 29, 2015 | 5.58 Bn |
| Dec 28, 2014 | 2.70 Bn |
| Sep 28, 2014 | 6.81 Bn |
| Jun 29, 2014 | 5.63 Bn |
| Mar 30, 2014 | 5.42 Bn |
| Dec 29, 2013 | 2.75 Bn |
| Sep 29, 2013 | 3.67 Bn |
| Jun 30, 2013 | 4.79 Bn |
| Mar 31, 2013 | 4.26 Bn |
| Dec 30, 2012 | 3.10 Bn |
| Sep 30, 2012 | 3.60 Bn |
| Jul 1, 2012 | 2.04 Bn |
| Apr 1, 2012 | 5.05 Bn |
| Jan 1, 2012 | 318.00 Mn |
| Oct 2, 2011 | 4.11 Bn |
| Jul 3, 2011 | 3.42 Bn |
| Apr 3, 2011 | 4.51 Bn |
| Jan 2, 2011 | 2.23 Bn |
| Oct 3, 2010 | 4.22 Bn |
| Jul 4, 2010 | 4.22 Bn |
| Apr 4, 2010 | 6.28 Bn |
| Jan 3, 2010 | 2.60 Bn |
| Sep 27, 2009 | 4.25 Bn |
| Jun 28, 2009 | 4.26 Bn |
| Mar 29, 2009 | 4.64 Bn |